Mraz Amerine & Associates Inc. Sells 63 Shares of Johnson & Johnson (NYSE:JNJ)

Mraz Amerine & Associates Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,358 shares of the company’s stock after selling 63 shares during the period. Johnson & Johnson accounts for 0.5% of Mraz Amerine & Associates Inc.’s holdings, making the stock its 28th biggest position. Mraz Amerine & Associates Inc.’s holdings in Johnson & Johnson were worth $2,813,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Nicholson Wealth Management Group LLC purchased a new stake in shares of Johnson & Johnson during the third quarter worth about $1,043,000. Legacy Capital Group California Inc. boosted its stake in Johnson & Johnson by 1.1% in the 3rd quarter. Legacy Capital Group California Inc. now owns 13,412 shares of the company’s stock worth $2,174,000 after purchasing an additional 142 shares in the last quarter. Woodard & Co. Asset Management Group Inc. ADV grew its position in Johnson & Johnson by 5.0% during the 3rd quarter. Woodard & Co. Asset Management Group Inc. ADV now owns 21,330 shares of the company’s stock worth $3,457,000 after purchasing an additional 1,013 shares during the last quarter. Investment Research & Advisory Group Inc. increased its stake in Johnson & Johnson by 1.3% during the 3rd quarter. Investment Research & Advisory Group Inc. now owns 14,968 shares of the company’s stock valued at $2,426,000 after purchasing an additional 189 shares in the last quarter. Finally, apricus wealth LLC raised its holdings in shares of Johnson & Johnson by 2.4% in the third quarter. apricus wealth LLC now owns 13,791 shares of the company’s stock worth $2,235,000 after buying an additional 322 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Sanford C. Bernstein upped their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. The Goldman Sachs Group cut their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, Royal Bank of Canada increased their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Stock Down 1.7 %

Shares of NYSE JNJ opened at $160.88 on Friday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company’s 50-day simple moving average is $163.38 and its 200-day simple moving average is $154.98. The firm has a market cap of $387.28 billion, a price-to-earnings ratio of 23.28, a price-to-earnings-growth ratio of 2.90 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.66 EPS. Equities analysts predict that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.08%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.